Therapeutic drug management of patients receiving mycophenolic mofetil or mycophenolate sodium using mycophenolic acid (MPA) concentrations is controversial. Considered to be less toxic compared to many of the other drugs used in immunosuppression regimens, MPA is not tolerated by all patients. For these patients, monitoring is useful in achieving desired therapeutic targets, reducing adverse effects, and individualizing dosing. We describe an LC-MS-MS that permits the measurement of MPA and 7-O-glucuronide mycophenolic acid (MPAG) in serum or plasma.
Chromatography, Liquid Glucuronides